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Introduction 
The infection of a seronegative host with HIV is the 
begin of a viral infection which Ieads after a long 
incubation period to a chronic disease process as a 
consequence of a virus-induced immune suppression. 
So far, the destruction of a lymphocyte subpopulation 
essential in mounting an immune response has been 
identified as an important pathogenetic mechanism in 
the development ofthe disease. However, beside HIV 
as the etiological agent for AIDS other viruses have 
been implicated as co-factors in the activation of a 
latent HIV infection. It has been observed that several 
DNA viruses transactivate HIV (13, 23, 25, 29). One 
of these is the human herpesvirus type 6 (HHV-6). 
This virus infects like HIV peripheral blood lympho-
cytes ( 1, 2, 3, 4, 16, 20) and therefore its isolation from 
AIDS patients has led to the hypothesis that a HHV-6 
infection may indeed interact with HIV and influences 
the course of AIDS. 
In the present study we have started to evaluate the 
presence of HHV-6 antibodies in a population of 
AIDS and control patients in a urban and non-urban 
area of Tanzania, Africa. From Dar-es-Salaam and 
from Bukoba serum specimens were available for test-
ing. Moreover, virus isolations were attempted from 
lymphocytes from AIDS and control patients to 
search for HIV as weil as HHV-6. The data obtained 
indicate that HHV -6 is indeed transactivating HIV 
infection in lymphocytes but is also widely distributed 
in persans not infected by HIV. Since many AIDS 
patients in our test groups do not reveal a HHV-6 
infection it is unlikely that HHV-6 plays a pathogenic 
role in the development of AIDS. 
Materials and Methods 
Collection and origin of samples 
Serum samples were collected in a rural hospital in 
Kagera, Tanzania. 330 sera were collected from 
adults, ranging in age from 15 to 62 years (mean 26 
years), 47% male, and from 100 children ranging in 
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age from 8 to 13 years (mean 10.5 years). Additional 
serum samp1es were drawn from patients ofthe Inter-
na! Medicine wards at the Muhimbili Medical Center 
(MMC), Dar-es-Salaam, Tanzania. 123 sera were col-
lected from adults, ranging in age from 18 to 60 years 
(mean 30 years), 60% male. During this visit to Dar-
es-Salaam we also took peripheral blood for isolation 
of lymphocytes. Specimen were obtained from 100 
subjects and were subsequently frozen in liquid nitro-
gen. Furthermore we received 42 sera from Ocean 
Road Hospital, Dar-es-Salaam, Tanzania. The pa-
tients' age ranged from 17 to 78 years (mean 35 years), 
40% male. 
Serological test for HIV 
Antibodies to HIV-1 or -2 were determined by enzyme 
linked immunosorbent assay (ELISA): one with 
whole virallysate ofHIV-1 (HTLV IIIb) on nitrocellu-
lose membrane (Serion, Virion, Würzburg, FRG), 
and the second (PEIA: peptide ELISA, Biochrom, 
Berlin, FRG) using microtiter plates coated with syn-
thetic peptides of HIV-1 (p17, p24, p31 and gp41) or 
of HIV-2 (p26 and gp36). Specimens that were posi-
tive on the initial test were subjected to Western blot 
analysis (WB). WB were considered positive when p24 
or gp41 were observed along with other bands indica-
tive for HIV infection. On1y specimens confirmed in 
this manner were considered true positives. 
Isolation of HIV and HHV -6 from PBL 
Periphera1 b1ood was drawn with anticoagulant. The 
patients PBL were separated from the buffer 1ayer on 
a ficoll gradient and frozen in liquid nitrogen. Fresh 
normal lymphocytes depleted of CD8+ cells (Dyna-
beads HLA dass 1, Dynal, Oslo, Norway) were stimu-
lated with 0.1% PHA-P (Difco, Detroit, USA) for 72 
hours then cocu1tivated with unstimulated CD8 de-
pleted patient's lymphocytes. The cultures were 
screened for HIV-1 or HHV-6 by indirect immuno-
fluorescence (IFA) or p24 antigen ELISA for HIV-1 
(DuPont, Bad Homburg, FRG) beginning on day 
three of cocultivation. 
Culture conditions 
Cells were cultured in RPMI 1640 (Biochrom, Berlin, 
FRG) supplemented for celllines with 10% fetal calf 
serum (Biochrom, Berlin, FRG) 5 mM glutamine (Bio-
chrom, Berlin, FRG), 10 J.Lg/ml gentamycine (Merck, 
Darmstadt, FRG). For primary cultures 20 U/ml 
interleukin 2 (ICN, Eschwege, FRG) and 500 U/ml 
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anti leukocyte interferon (Renner, Dannstadt, FRG) 
were added. During the first three days of cocultiva-
tion 2 p.g/ml polybrene (Aldrich, Steinheim, FRG) 
was added. 
Celllines 
MT-4 cells (8, 20) were kindly provided by B. Zorr, 
Berlin, FRG. Raji cells (10), BjAB cells (19) and 
P3HR 1 cells ( 1 0) were kindly provided by A. Pohl, 
Würzburg, FRG. 
Cytofluorographic analysis (FACS) 
For two colour staining 1.5 x 106 lymphoid cells were 
fixed with 3.5% formaldehyde (FA) for 5 min. and 
subsequently treated for 30 min. at 4 °C with human 
serumpositive for HHV-6 and goat anti human lgG 
Fab fragment phycoerythrein labeled (PE) (Dianova, 
Hamburg, FRG) for 30 min. at 4 °C. For intracellular 
staining we pretreated the cells at room temperature 
(RT) with 3.5% FA for 25 min., with 0.25% Triton X 
100 (Sigma, St. Louis, USA) for 15 min. and blocked 
with 10% goat serum foranother 15 min. We stained 
for HIV-1 with monoclonal antibody p24 1:50 (Dia-
nova, Hamburg, FRG) and goat anti mause lgG 
fluorescein isothiocyanate (FITC) labeled for 60 min. 
at RT each. The fluorescence intensity was analysed 
by a FA CSCAN flow cytometer (Becton and Dicken-
san, Heidelberg, FRG). Dead cells and debrids were 
excluded from analysis by selective gating based on 
low angle light scatter. 
Electron microscopy (EM) 
Single or double infected MT-4 cells were sedimented 
at 200 g for 5 min. and the pellet incubated with 1.25 % 
glutaraldehyde in 0.1 M cacodylate-HCL buffer, 
0.1 M sucrose, and 2 mM CaCl2, pH 7.2 for I h, post-
fixed with 1 % Os04 in the same buffer for 2.5 h and 
<, for transmission electron microscopy as 
pre,vimislv described (3). 
and chloramphenicol acetyltransferase 
-) assay 
107 cells were transfected with 10 p.g indicator 
(pHIV -1 CA T) and either 10 p.g tat expres-
(pCV-1)or 10 p.gpBR 322 bythe DEAE-
methorl (27). Cells were harvested 36 h after 
· and processed as described (7). CA T -as-
pertor·me:d with equal amounts of protein as 
with a commercial protein assay (Biorad, 
FRG), 0.12 p.Ci 14C-chloramphenicol and 
25 
0.8 mM acetyl-CoA. Assays were incubated at 37 °C 
for 4 h. Acetylated chloramphenicol was separated 
from unacetylated by ascenrling thin-Iayer chromato-
graphy, and quantification was done by cutting out 
the spots from the chromatography plate anrl liquid 
scintillation counting. 
Herpesvirus serology 
HHV-6: The patients sera were titered for HHV-6 IgG 
antiborlies using MT-4 cells infected with HHV-6 
(Tanzanian isolate). 80% infected cells were mixed 1:5 
with uninfected MT-4 cells. Infected cells were har-
vested for testing, when about 50% were infected and 
transformed to blasts (within 5 days). After rinsing of 
the cells, cells were dried, fixed in acetone for 5 min. 
and stored at -20 oc. Uninfected MT-4 cells were used 
as negative control. Incubation time with sera and 
conjugate (FITC labeled goat anti human IgG Fab 
fragment 1:50, Dianova, Hamburg, FRG) was 1 h at 
37 oc. The slides were finally washed three times and 
mounted for UV-IFA. IFA was regarded positive 
with a titer of 1:30 and above. 
EBV: IFA was used to detect lgG antibodies to EBV 
capsid antigen (EBV-VCA), to EBV nuclear antigen 
(EBNA) and EBV early antigen (EA). Antihoclies to 
EBV-VCA were determined on acetone fixed cell 
smears with P3HR1 cells that were incubated with test 
sera 1:10 anrl then with FITC conjugated rabbit an-
tibodies to human lgG 1:20 (Dakopatts, Hamburg, 
FRG) both for 1 h at 37 oc. For EBV-EA testing we 
inducerl Raji cells with 10 ng/ml phorbol-12-myrista-
te-13-acetate (PMA, Sigma, St. Louis, USA) for t.wo 
days. Cells and slides were treated following our 
standard protocol for EBV-VCA IF A. The prepara-
tions were finally counterstained in Evans blue. Each 
testwas run with positive anrl negative control sera. In 
testing for EBNA antihoclies we used methanol-fixed 
Raji cells. BjAB cells were used as negative control. 
Preparations were successively overlaid with test sera, 
I: 10, serum from an indivirluallacking antihoclies to 
EBV, 1: I 0, source of complement, and finally, FITC 
labeled rabbit antibodies to C3c globulins (Dako-
patts, Hamburg, FRG), 1:20, each for 30 min. at 
37°C. 
HSV-1, CMV, VZV: ELISA test kits were used for 
testing patients sera, 1:40, for IgG antiborlies (Beb-
ring, Mannheim, FRG). 
Results 
During our attempts to isolate retrovirus from Tan-
zanian PBL we recovered also HHV-6 (no. T9, no. 
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Fig. 1: E/ectron micrograph of an MT-4 cel/ infected with HHV-6 (T9). Magnification 5600 x 
T87) from 2 HIV negative patients. Between days 7 
and 12 of cocultivation, large refractile cells appeared 
and became the predominant cell type. Throughout 
the passage series, reverse transcriptase was not de-
tected in cultures with extensive CPE. However, EM 
revealed the characteristic structure of a herpesvirus 
(Fig. I). 
Southern blotting of restriction enzyme digests of 
DNA from cultures of infected ,cells demonstrated 
hybridisation with HHV-6 probes, obtained from B. 
Honess (probe pHD 5). The infection was easily pas-
saged on primary PBL cultures. Out of a large number 
of different celllines only Jurkat, CEM, HSB-2, and 
MT-4 cells were susceptible to our HHV-6 isolates. 
Double infection experiments 
To investigate a possible interaction of HIV-1 and 
HHV -6 we established a double infection model based 
on MT-4 cells (Fig. 2). To achieve this we subcloned 
MT-4 cells (MT-4-T5) permanently infected with 
HIV-1 (Tanzanian isolate no. T5). This cell clone did 
no Ionger show any CPE for HIV-1 and produced 
103 - 104 infectious particles/ml supernatant. Growth 
pattern and viability did not differ from uninfected 
MT-4 cells. For double infection experiments we su-
perinfected the MT-4-T5 clone with cell free HHV-6 
virus (T9, T87) at a multiplicity of infection of 0.1 
TCID50/cell. The CPE for HHV-6 on the superin-
fected population and on single infected MT -4 cells 
occurred within 8 to 9 days. Cells infected only with 
HHV-6 died within 14 to 16 days p.i. Double infected 
populations died three days earlier. A marked in-
crease in p24 antigen in supernatant of MT4-T5 was 
detected beginning at day 6 p.i. In contrast to the 
single infected cell clone we found a two to threefold 
increase of p24 in the supernatant of double infected 
cell cultures. To investigate the course of double infec-
tion over time we performed F ACS analysis (Fig. 3). 
Single infected MT -4 cells on day 13 p.i. expressed 
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Fig. 2: Electron micrograph of double infected MT-4 cells (HJV-1 and HHV-6). Arrow heads indicate budding HIV particles. Seen intracellularly 
is the characteristic structures of a herpesvirus (asterisk). Magnification 31 500 x 
nearly 100% HHV-6 proteins at a mean of fluores-
cence (log PE) of 400. Double infected cells (MT -4-T5 
+ HHV-6, strain T9) at day 13 expressed HHV-6 
proteins at a similar percentage but the fluorescence 
intensity (mean log PE) for HHV-6 was dramatically 
less when compared to single infected population (400 
versus 127). Additionally the percentage of HIV-1 
positive cells decreased over the course of double 
infection from 80% in the beginning to 34% on day 
13. 
As shown in Fig. 4 HHV-6 is able to activate trans-
cription from the HIV-1 LTR in trans. HHV-6 in-
fected MT-4 cells and uninfected MT-4, MT-2 and H9 
cells were transfected with indicator plasmid pHIV-1 
cat tagether with tat expression plasmid pCV-1 or 
with non-specific DNA (pBR322) to keep the DNA 
amount constant. In uninfected cells, transactivation 
was only observed by cotransfection of pHIV-1 cat 
and pCV-1 (compare lanes 1 and 2, 4 and 5, 7 and 8). 
In contrast, in HHV-6 infected cells, transcription 
from the HIV -1 L TR is transactivated in the absence 
of pCV -1 ( compare 1anes 7, 10 and 13). The extent of 
transactivation is correlated to the percentage of 
HHV-6 infected cells as judged by immunofluores-
cence (lane 10: 5% HHV-6 infected cells, 1ane 13: 
<1% HHV-6 infected cells). 
Serological evidence of Herpesviruses and HIV -1 
To ascertain whether there was any correlation be-
tween the antibody prevalence of HIV-1 and herpes-
viruses we screened 493 sera of adult patients and 100 
sera of school children from three Tanzanian hospi-
tals for lgG antibodies to HIV-1, HSV-1, CMV, VZV, 
EBVand HHV-6 (Tab1e 1). 49% ofthe adults showed 
antibodies to HIV-1 confirmed by Western blotting. 
All chi1dren were HIV-1 seronegative. Of the 593 
patients tested for HHV-6 antibodies, 46% of the 
adults were seropositive (i.e. 227) and 37% of the 
children (i.e. 37) when 1:30 was chosen as discrimina-
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Fig. 3: FACSCAN ana/ysis: Expression of HIV-1 and HHV-6 on 
MT-4 cel/s. Two co/our immunofluorescence analysis ( dot p/ot) of 
HHV-6 infected MT-4 ce//s (lane A) and MT-4-TS (subclone per-
manently infected with HIV-1, lane B) at different times p.i. In this 
case the y axis indicates the Ievel of positive HHV-6 expression 
(log PE) whereas the x axis shows HIV-1 expression (/ogFITC). Ce// 
percentages are indicated in the quadrants. 
tive IgG titer in the IF A. In regard to the titer there 
was no difference between adults and children. The 
330 sera collected in a rural hospital in Kagera had a 
prevalence of 38 %, in sera from Muhimbili Medical 
Center we found 50% of 123 sera and in sera from 
Ocean Road Hospital, 100% of 42 serapositive for 
HHV -6. A difference in the rate of seropositivity 
against HHV -6 was found when men and women 
were compared. 41% of the HHV-6 negative group 
(i.e. 83) and 62% ofthe HHV-6 positive patients with 
a titer above 1:480 (i.e. 21) were women. We did not 
find any correlation between HHV-6 positivity or titer 
and HIV-1. 45% ofHIV-1 negative and 48% ofHIV-
1 positive patients were HHV -6 positive. 51 % of the 
HHV -6 positive sera with a titer below 1: 100 and 45% 
of the sera with a titer above 1 :480 were HIV -1 sero-
positive. Of 493 sera we obtained, 298 patients had 
well defined diseases (AIDS related complex, AIDS, 
tuberculosis, malaria and sexually transmitted dis-
eases). We first tried to correlate the occurrence of 
antibodies against HIV-1 with the presence of anti-
bga-Schriften 111990 
bodies against EBV antigenssuch as EBNA, EA and 
VCA (indicative for respective an old, fresh or reacti-
vated infection) and with the antibody titer against 
HHV-6. With respect to the serological markers no 
correlation was found between EBV and HIV nor 
between HHV-6 and HIV nor between EBV and 
HIV-1 and HHV-6. Further no correlation was seen 
between the above mentioned diseases (ARC, AIDS, 
etc.) and herpesvirus-, especially HHV-6 infection. 
The same sera were tested for antibody to other her-
pesviruses but antibody to HHV-6 did not correlate 
with the presence ofantibody to HSV-1, CMV, VZV, 
and EBV, indicating that a positive anti HHV -6 IF A 
was specific and no correlation to other herpesviruses 
was observed. 
Discussion 
During our attempts to isolate retrovirus from Tan-
zanian PBL we cocultivated patients lymphocytes 
with HHV-6 and HIV negative donor PBL. Interes-
tingly we isolated HHV -6 from two HIV seronegative 
patients. In cantrast to other authors (23) we could 
not isolate HHV-6 from PBL of HIV seropositive 
patients. This may be due to the totally different 
growth pattern of both viruses and to the high isola-
tion frequency for HIV -1 using our cocultivation me-
thod (>90 %). HIV-1 replicates in vitro much more 
rapid1y than HHV-6. Normally we detect HIV-1 in 
primary cocultivation beginning on day 3 with maxi-
mum on day 8 whereas the detection of our HHV-6 
strains began at day 10. In accordance with published 
results of other authors (18) we can show that our 
HHV-6 isolates from Tanzania are able to activate the 
transcription of HIV -1 in trans (Fig. 4 ). Our kinetical 
study of double infected MT -4 cells indicate: 1. HHV-
6 Ieads to an enhancement of HIV-1 replication in 
early stages of double infection; 2. in later stages of 
double infection HHV-6 replication prevails over 
HIV -1 replication; 3. fluorescence intensity for HHV-
6 expression in double infected populations does not 
reach the level of single infected MT -4 cells; 4. double 
infected cells are dying more rapidly than single in-
fected cells. 
Since HHV -6 is capable of increasing HIV -I replica-
tion, infection by HHV-6 will consequently increase 
the cytopathic effect on coinfected CD4+ cells in vitro. 
Because replication of HHV -6 itself is cytopathic for 
the same cells a synergistic effect may take place and 
progressively increase cell death. In this fashion 
HHV -6 infection or reactivation in immunosup-
pressed patients, for example AIDS patients, may 
exacerbate or modify the disease. 
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Fig. 4: CAT assay: HHV-6 infeeted MT-4 eells and uninfeeted MT-4, MT-2 and H9 cells were Iransfeeted with indieator plasmid pHIV-Ieat 
tagether with tat expression plasmid pCV-1 or with non-speeifie DNA. In uninfeeted eells transaetivation was only observed by cotransfeetion of 
pHIV-1 eat and pCV-1 (eompare lanes I and 2, 4 and 5, 7 and 8). In HHV-6 infeeted cells transaetivation ofthe HIV-1 LTR is also observed in 
cells, Iransfeeted only with pHIV-1 eat (eompare lanes 7. 10 and 13). 
percenl 
Table 1: Seroprevaleneefor antibody against HIV-1, HHV-6, EBV, 
VZV, HSV-1, CMV (n = 493) 
Many serological studies found preva1ences for anti-
body against HHV-6 ranging from 20 to 98% depen-
ding on the investigated populations and the discrimi-
nating titers (16, 17, 23, 24). With our method and a 
discriminating titer of 1:30 we found a seroprevalence 
for HHV -6 of 46% in adults and 37% in children. 
Significantly higher seroprevalences have been re-
ported (5, 14, 15, 24) which compare better to our data 
ifwe could accept in IFA titer of 1:10 as positive. But 
in IF A we observed for African sera very high percen-
tage of non specific reactions ( appwximately 25 %) on 
HHV -6 infected PBL, cord blood and MT -4 cells 
when using a discriminating titer of 1:10. In cantrast 
to other studies the preva1ence of HHV -6 in persans 
infected with HIV-1 or having AIDSsyndrome was 
not significantly high er than in HIV -1 negative pa-
tients (Table 1). Ablashi et al. (1988) found a sewpre-
valence for HHV-6 of 26% in a control group versus 
70% in a group of HIV infected patients. It is of 
30 
importance to state the differing transmission routes 
of HIV when African and American or European 
populations are compared. In Africa, HIV -1 infection 
has already entered the general population whereas in 
American or Europe the typical risk groups are still 
homosexuals, hemophiliacs and i.v. drug abusers. 
This may be one explanation for our findings. 
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